• Discontinuing worldwide sales of ACURATE Aortic Valve Systems.
• No longer seeking approval with US FDA or in other geographies.
• Still expects to achieve 2Q and FY25 sales and earnings guidance.
• Is NOT reaffirming the GAAP guidance for the above.
• Cardiology makes up 65% of projected 2025 sales.
• Given the fact that it still expects to meet 2025 targets (albeit non-affirming actual GAAP numbers) we would say that this is more of an equity story for now but does raise concerns in a key area for the firm.
Find more articles and bullets on these widgets:
From a little earlier: 2RZ5 97.25/97.00 put spread, paper sells for 2.75 on 10k.